Background: Perineural dexamethasone has been shown to improve analgesia in single injection supraclavicular block. Systemic mechanism of action of dexamethasone along with safety concerns of perineural route of administration has prompted the investigation of intravenous route as an alternative. Aims: We aim to compare the effects of dexamethasone as an additive to local anesthetic when used via perineural and intravenous route in terms of duration of analgesia and onset of motor and sensory block. Settings and Design: The study was done as a prospective comparative observational study conducted in a tertiary care hospital in India among 50 patients during a period of 1 year. Materials and Methods: Twenty-five patients aged 18–60 years, belonging to the American Society of Anesthesiologists physical status Classes I and II, receiving supraclavicular block with 0.5% bupivacaine and perineural dexamethasone were compared with similar number of patients receiving the block along with intravenous dexamethasone. Duration of analgesia, onset of sensory block, and onset of motor block were studied. Statistical Analysis: The results were analyzed using Chi-square test for qualitative variables and unpaired t -test for quantitative variables. Results: The duration of analgesia in the group receiving perineural dexamethasone (Group DP) 817.2 ± 88.011 min was comparable to the group receiving intravenous dexamethasone (Group DI) 858.00 ± 86.168, with a P = 0.104. Time to onset of sensory block in Group DP (10.20 ± 1.443 min) was significantly faster than that of Group DI (11.60 ± 1.443) with a P = 0.001. Time to onset of motor block in Group DP (13.92 ± 1.754 min) was significantly earlier than that of Group DI (14.96 ± 1.274 min) with a P = 0.02. Conclusion: It is concluded from this study that intravenous and perineural dexamethasone equally prolongs the duration of analgesia in supraclavicular block. However, perineural dexamethasone resulted in a faster onset of motor and sensory blockade.
Introduction: Cisatracurium and atracurium are non-depolarising muscle relaxants belonging to benzylisoquinolinium group. Intubating dose of cisatracurium is found to be safer than atracurium owing to the histamine release and resultant respiratory and cardiac side-effects associated with the latter. However, intubating conditions of twice the ED95 dose (2xED95) of cisatracurium are not as satisfactory as equipotent dose of atracurium because of its higher potency. Aim: To compare the time of onset, intubating conditions and mean duration of action of three and four times ED95 doses (3 and 4xED95) of cisatracurium with 2xED95 dose of atracurium so as to find out an ideal intubating dose of cisatracurium that is comparable with 2xED95 of atracurium. Materials and Methods: The present study was a prospective cohort study that included 102 patients who underwent elective laparoscopic cholecystectomy. They were divided into three groups of 34 each to receive atracurium 0.5 mg/kg (group A), cisatracurium 0.15 mg/kg (group B) or cisatracurium 0.2 mg/kg (group C) for intubation. Onset and duration of neuromuscular block were assessed using Train Of Four (TOF) stimuli. Total time for intubation and mean intubation scores were also noted. Statistical analysis was done using Statistical Package for the Social Sciences (SPSS) software version 18.0. Qualitative data were compared using Chi-square test and quantitative data compared using Analysis of Variance (ANOVA). Results: Onset of neuromuscular blockade in groups A, B and C were 292.06±61.486, 204.71±39.407 and 120.88±37.284 seconds (p-value <0.001), respectively. Mean intubation score was highest in group C along with least intubating time (p-value <0.001). The mean duration of action in groups A, B and C were 40.44±5.275, 48.24±5.888 and 63.38±7.659 minutes, respectively (p-value <0.001). Conclusion: The 3 and 4xED95 doses of cisatracurium are superior to 2xED95 dose of atracurium in providing faster onset of action, better intubating conditions, shorter intubation time and longer duration of action. The 4xED95 dose of cisatracurium may be considered for rapid intubation in two minutes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.